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Inhibition of In-Stent Stenosis by Oral Administration of
Bindarit in Porcine Coronary Arteries
Armando Ialenti, Gianluca Grassia, Peter Gordon, Marcella Maddaluno, Maria Vittoria Di Lauro,
Andrew H. Baker, Angelo Guglielmotti, Antonio Colombo, Giuseppe Biondi,
Simon Kennedy, Pasquale Maffia
Objective—We have previously demonstrated that bindarit, a selective inhibitor of monocyte chemotactic proteins (MCPs),
is effective in reducing neointimal formation in rodent models of vascular injury by reducing smooth muscle cell
proliferation and migration and neointimal macrophage content, effects associated with the inhibition of MCP-1/CCL2
production. The aim of the current study was to evaluate the efficacy of bindarit on in-stent stenosis in the preclinical
porcine coronary stent model.
Methods and Results—One or 2 bare metal stents (Multi-Link Vision, 3.5 mm) were deployed (1:1.2 oversize ratio) in the
coronary arteries of 42 pigs (20 bindarit versus 22 controls). Bindarit (50 mg/kg per day) was administered orally from
2 days before stenting until the time of euthanasia at 7 and 28 days. Bindarit caused a significant reduction in neointimal
area (39.4%, P0.001, n9 group), neointimal thickness (51%, P0.001), stenosis area (37%, P0.001), and
inflammatory score (40%, P0.001) compared with control animals, whereas there was no significant difference in the
injury score between the 2 groups. Moreover, treatment with bindarit significantly reduced the number of proliferating
cells (by 45%, P0.05; n6 group) and monocyte/macrophage content (by 55%, P0.01; n5–6 group) in stented
arteries at day 7 and 28, respectively. These effects were associated with a significant (P0.05) reduction of MCP-1
plasma levels at day 28. In vitro data showed that bindarit (10–300 mol/L) reduced tumor necrosis factor- (50
ng/mL)–induced pig coronary artery smooth muscle cell proliferation and inhibited MCP-1 production.
Conclusion—Our results show the efficacy of bindarit in the prevention of porcine in-stent stenosis and support further
investigation for clinical application of this compound. (Arterioscler Thromb Vasc Biol. 2011;31:2448-2454.)
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Increasing evidence suggests that monocyte chemotacticprotein (MCP)-1/CCL2 plays an early and important role
in the formation of intimal hyperplasia and in-stent resteno-
sis1 by increasing macrophage accumulation and smooth
muscle cell (SMC) proliferation and migration.2,3 Deletion of
the MCP-1 gene, blocking MCP-1 signaling or MCP-1
receptor CCR2 decreases neointimal hyperplasia after
balloon- and stent-induced injury in several animal mod-
els.4–7 Similarly, catheter-based adenovirus-mediated anti-
monocyte chemoattractant gene therapy attenuates in-stent
neointimal formation in monkeys.8 These data suggest that an
antiinflammatory/antiproliferative strategy targeting MCP-1
might be an appropriate and reasonable approach for the
prevention of neointimal formation and in-stent restenosis.
Bindarit is a selective inhibitor of MCP-1/CCL2, MCP-3/
CCL7, and MCP-2/CCL8 synthesis9 that shows potent anti-
inflammatory activity in a number of experimental models,
including nephritis, arthritis, pancreatitis, and colitis,10–13 as
well as reducing myocardial and renal dysfunction in swine
renovascular hypertension.14,15 Phase II clinical trials have
shown that bindarit is well tolerated and significantly reduced
urinary MCP-1 and albumin excretion in kidney disease.10,16
Interestingly, we have already shown that oral administra-
tion of bindarit is effective in reducing neointimal formation
in both nonhyperlipidemic and hyperlipidemic rodent models
of vascular injury by a direct effect on SMC proliferation and
migration and by reducing neointimal macrophage content,
effects associated with the inhibition of MCP-1/CCL2 pro-
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duction.17 However, there are many instances where rodent
models of neointimal formation have lacked efficacy in
predicting the success of interventions to inhibit restenosis in
humans.18–20 Therefore, the aim of the present study was to
evaluate the efficacy of bindarit on in-stent stenosis in the
preclinical porcine coronary stent model.
Methods
Animals
Male large-white/Landrace intact pigs (20–24 kg, 10 weeks old,
SAC Commercial Ltd, Edinburgh, United Kingdom) on a 12-hour
light/dark cycle, with free access to water and twice-daily food, were
maintained at the Biological Procedures Unit, University of Strath-
clyde. All procedures were performed in accordance with local
ethical and UK Home Office regulations.
Bindarit Administration
Bindarit (2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy]
propanoic acid, MW 324.38) was synthesized by Angelini (Angelini
Research Center, Aziende Chimiche Riunite Angelini Francesco,
Rome, Italy). Pigs were dosed with bindarit (50 mg/kg per day) in 2
divided doses administered morning and evening (12-hour interval).
Dosing started 2 days before stenting and continued daily for the 7
or 28 day follow-up period. The bindarit powder was mixed with
yogurt and squirted into the pigs’ mouths. Control animals received
vehicle alone (yogurt containing no bindarit).
The dose regimen of bindarit was chosen based on earlier results
from a swine renovascular hypertension model14,15 and pharmacoki-
netic studies in male Go¨ttingen minipigs (10–12 kg, Harlan) show-
ing that bindarit is well absorbed when administered by the oral
route. Single-dose oral administration of 25 mg/kg resulted in a Cmax
level of 50 g/mL (corresponding to 154 mol/L), Tmax 2 hours, and
t1⁄2 10 hours (Product Data Sheet, Angelini Research Center),
corresponding to concentrations able to inhibit MCP-1 production
and inflammation.14,15,17,21
Porcine Coronary Stent Model
Pigs were premedicated with aspirin (150 mg oral, Teva, Leeds,
United Kingdom) and clopidogrel (150 mg oral, Sanofi-Aventis,
Guildford, United Kingdom) over a 24-hour period before surgery.
Pigs were sedated by an injection of tiletamine/zolazepam (100 mg
Zoletil IM, Virbac, Suffolk, United Kingdom) and propofol (30 mg
Rapinovet IV, Schering-Plough, Welwyn Garden City, United King-
dom). All animals were intubated and anesthesia maintained
throughout the procedure using a mixture of isoflurane (1% to 2%,
Abbott Laboratories Ltd., Maidenhead, UK) in oxygen/nitrous oxide.
Unfractionated heparin (100 U/kg IV, Leo Laboratories, Princes
Risborough, United Kingdom) was given at the start of the proce-
dure. Access to the coronary arteries was achieved via the left
femoral artery, using standard 6 French sheaths and coronary guiding
catheters. In the majority of animals, stents (Multi-Link Vision,
3.515 mm, Abbott) were placed in 2 of the 3 coronary arteries (left
anterior descending, left circumflex, and right coronary arteries)
under fluoroscopic guidance. Nine bindarit-treated animals (16
stents) and 10 control animals (17 stents) were used for the
morphometric analysis. Six bindarit-treated animals (12 stents) and 6
control animals (12 stents) were used for the proliferating cell nuclear
antigen analysis. Five bindarit-treated animals (10 stents) and 6 control
animals (12 stents) were used for evaluating the effect of bindarit on
monocyte/macrophage infiltration. ECG and mean arterial pressure
were recorded continuously. Stents were deployed at inflation
pressures necessary to produce a stent to artery ratio of 1.2:1. After
sheath removal, the femoral artery was ligated, and the leg wound
was closed and sutured. All animals were given buprenorphine (0.15
mg of Vetergesic IM, Alstoe Ltd, York, United Kingdom) to provide
analgesia and ampicillin (350 mg of Amfipen LA IM, Intervet,
Welwyn Garden City, United Kingdom) for antibiotic cover, imme-
diately after the procedure. Animals were recovered and received a
normal diet, with supplementation of 75 mg of aspirin orally every 2
days and 75 mg of clopidogrel orally every 2 days for the duration
of the study.
Tissue Processing and Morphometric Analysis
To determine whether bindarit was successful in reducing in-stent
stenosis, stents from bindarit-treated animals and controls were
examined histologically. One control animal failed to develop
vascular injury in both implanted stents and was excluded from the
study. Seven or 28 days after stent implantation, the pigs were
euthanized with an overdose of pentobarbital (200 mg/mL pentobar-
bitone, Merial, Harlow, United Kingdom) via the marginal ear vein,
and the stented arteries were removed from the heart and flushed
with normal saline to remove nonadherent thrombus. The coronary
arteries harvested 7 days after stent implantation were divided into 2
parts at the center of the stent. The proximal part was used for protein
extraction, and the distal portion was fixed in 10% formaldehyde and
used for immunohistochemical staining.
For morphometric analysis, stented coronary arteries harvested at
28 days were fixed in formal saline (24 hours) and dehydrated in
pure acetone before resin embedding in glycol methacrylate (Tech-
novit 8100, Kulzer, Wehrheim, Germany) following the manufac-
turer’s instructions. Sections (4–12 in controls and 5–12 in bindarit)
were obtained from the proximal to distal portion of the stent using
a Buehler Isomet 1000 rotary precision saw (Buehler, Lake Bluff, IL)
and mounted on a glass slide. Sections were then ground and
polished using a Buehler Metaserv 2000 grinder to reduce the
thickness to 10 m and give a uniform surface for staining and
microscopic evaluation. Sections were stained using hematoxylin/
eosin, and images were acquired using a Leica DM LB2 microscope
and Leica DFC320 digital camera. After digitalizing, histomorpho-
metric measurements were performed with ImageJ (NIH Imaging,
http://rsbweb.nih.gov/ij). Borders were manually traced for lumen
area, area circumscribed by the internal elastic lamina (IEL), the
border of the external elastic lamina (external elastic lamina area,
vessel area) and stent circumference as the linear distance from strut
to strut around the circumference of the stent.22 The neointimal and
medial areas were computed as follows: neointimal areaIEL area
minus lumen area; medial areaexternal elastic lamina area minus
IEL area. Furthermore, percentage area of stenosis was calculated
as 100(1lumen area/IEL area). Neointimal thickness (defined
as the minimum distance between the strut and the lumen) was
determined at each strut site and calculated as mean for each stented
coronary segment. Results are expressed as the mean value from both
stents per animal.
Injury and Inflammatory Score
The injury score was calculated as previously reported by Gunn et
al23 Briefly, we considered both deep injury and stretch as follows:
0no impression of metal on media; 1deformation of the IEL by
45°; 2deformation of the IEL by 45°; 3rupture of the IEL;
4rupture of the external elastic lamina (that is complete medial
rupture).
The inflammatory score was calculated as previously reported by
Kornowski et al.24 Briefly, we considered the extent and density of
the inflammatory infiltrate in each individual strut, and the grading
used was as follows: 0no inflammatory cells surrounding the strut;
1light, noncircumferential lymphohistocytic infiltrate surrounding
the strut; 2localized, moderate to dense cellular aggregate sur-
rounding the strut noncircumferentially; 3circumferential dense
lymphohistiocytic cell infiltration of the strut. The injury and
inflammatory score for each cross section were calculated as the sum
of the individual injury or inflammatory scores, divided by the
number of struts in the examined section.
Preparation of Tissue Total Protein Extracts
All the extraction procedures were performed on ice with ice-cold
reagents. Briefly, frozen porcine coronary arteries were crushed into
a fine powder under liquid nitrogen and resuspended in an adequate
volume of Cell Extraction Buffer containing 10 mmol/L Tris, pH 7.4;
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2 mmol/L Na3VO4; 100 mmol/L NaCl; 1% Triton X-100; 1 mmol/L
EDTA; 10% glycerol; 1 mmol/L EGTA; 0.1% SDS; 1 mmol/L NaF;
0.5% deoxycholate; 20 mmol/L Na4P2O7, supplemented with
1 mmol/L phenylmethylsulfonyl fluoride and Protease Inhibitor
Cocktail (P2714) (Sigma, Dorset, United Kingdom) just before use
and then centrifuged for 15 minutes at 13000g. Supernatant was
transferred to a fresh tube and stored at 80°C. Protein concentra-
tion was determined using the Bio-Rad protein assay kit.
Western Blot Analysis
The levels of proliferating cell nuclear antigen (PCNA) or CD68
expression were evaluated in total protein extracts from porcine
coronary arteries 7 and 28 days after stent implantation respectively.
Equivalent amounts of protein (60 g) from each sample were
electrophoresed on a 10% discontinuous polyacrylamide gel. The
proteins were transferred onto nitrocellulose membranes according
to the manufacturer’s instructions (Bio-Rad, Milan, Italy). The
membranes were saturated by incubation with 10% milk buffer for 3
hours at room temperature and then incubated with mouse anti-
PCNA antibody (1:3000, PC10, Sigma), mouse anti-CD68 (1:1000,
AbD Serotec, Kidlington, United Kingdom), or mouse anti--actin
antibody (1:5000, Sigma) overnight at 4°C. The membranes were
washed 3 times with 0.5% Triton X-100 in PBS and then incubated
with anti-mouse immunoglobulin coupled to peroxidase (1:2000,
PerkinElmer, Monza, Italy) for 1 hour at room temperature. The
immune complexes were visualized by enhanced chemilumines-
cence (Amersham ECL, GE Healthcare, Milan, Italy). ImageJ was
used for densitometric analysis. Results are expressed as arbitrary
units of PCNA or CD68 protein levels, normalized to protein levels
of -actin.
Immunohistochemical Analysis
After fixation of the coronary arteries harvested at day 7, the stent
struts were gently removed with microforceps under a dissection
microscope. The specimens were dehydrated, embedded in par-
affin, and cut into 7-m-thick slices. After antigen retrieval in
citrate buffer, the sections were incubated with monoclonal
mouse anti-PCNA antibody (1:250, PC10, Sigma) and biotinyl-
ated anti-mouse secondary antibody (1:200, DakoCytomation,
Milan, Italy). Slides were treated with streptavidin– horseradish
peroxidase (DakoCytomation) and exposed to diaminobenzidine
chromogen (DakoCytomation) with hematoxylin counterstain.
The proliferating cell number in the porcine coronary arteries was
scored in 10 random fields (20 objective) for 10 sections from
each artery, under blind conditions, and expressed as the percent-
age of total arterial (medial plus neointimal) cells positive for
PCNA 7 days after stent implantation.
Cell Culture
Porcine vascular SMCs were isolated from coronary arteries of male
pigs as previously described25 and grown in Dulbecco’s modified
Eagle medium (Cambrex Bio Science, Walkersville, MD) supple-
mented with L-glutamine (Lonza, Treviglio, Italy), 10% fetal bovine
serum (Lonza, Treviglio, Italy), 100 U/mL penicillin (Lonza), and
100 g/mL streptomycin (Lonza) in a humidified incubator at 37°C
in 5% CO2. Before initiation of assays, the SMCs were switched into
Dulbecco’s modified Eagle’s medium supplemented with 0.1% fetal
bovine serum for 48 hours, to achieve quiescence. Studies were
performed with cells at passages 3 to 6.
Proliferation Assay
Cell proliferation was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide. SMCs were plated on 48-well
plastic culture plates at a density of 1.5104 cells/well and then
incubated with Dulbecco’s modified Eagle’s medium containing
human tumor necrosis factor- (TNF-) (50 ng/mL, R&D Systems,
Minneapolis, MN) for 72 hours in the presence or absence of bindarit
(10–300 mol/L). The absorbance values were obtained with an
ELISA assay reader (630 nm).
ELISA for MCP-1 Protein
MCP-1 levels were measured in plasma samples obtained 28 days
after stent implantation and in the SMC supernatants. SMCs plated
as above were stimulated with human TNF- (50 ng/mL) in the
presence or absence of bindarit (10–300 mol/L). After 12, 24, 48,
Figure 1. A and B, Representative photomicrographs (hematoxy-
lin/eosin staining) showing the effect of bindarit on in-stent stenosis
28 days after stent deployment (A: control group; B: bindarit).
Scale bar1 mm. C and D, Representative photomicrographs
showing the reduction in inflammatory cell influx in the bindarit-
treated group (D) vs control group (C). Scale bar100 m.
Figure 2. Effect of bindarit on neointimal area (A), neointimal
thickness (B), percentage of stenosis (C), inflammatory score
(D), lumen area (E), and injury score (F). Data per single animal
and means (bars) are presented. ***P0.001 vs control group.
ns indicates not significant.
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and 72 hours, media were collected and centrifuged at 2000g for 15
minutes at 4°C, and supernatants were used for ELISA according to
the manufacturer’s instructions (Pig CCL-2 ELISA kit, Bethyl
Laboratories, Montgomery, TX). The results are expressed as pg/mL.
Statistical Analysis
Results are expressed as meanSEM of n animals for in vivo
experiments and meanSEM of multiple experiments for in vitro
assays. The Student t test was used to compare 2 groups, and
ANOVA (2-tailed probability value) was used with the Dunnett post
hoc test for multiple groups using GraphPad Instat 3 software (San
Diego, CA). A probability value of less that 0.05 was taken to
indicate statistical significance.
Results
Morphometric Analysis
Representative stented artery sections obtained 28 days after
implantation are shown in Figure 1. Morphometric assessment
showed a significant reduction in neointimal area (4.030.46
versus 6.650.44 mm2, P0.001) (Figure 2A), neointimal
thickness (270.226.92 versus 551.0649.94 m, P0.001)
(Figure 2B), percentage of stenosis (47.563.42% versus
74.972.71%, P0.001) (Figure 2C), and inflammatory score
(1.100.06 versus 1.830.11, P0.001) (Figure 2D) in the
bindarit-treated group compared with control animals. More-
over, in the bindarit-treated group, the lumen area was signifi-
cantly increased compared with the control group (4.430.33
versus 2.120.15 mm2, P0.001) (Figure 2E). No significant
differences were detectable in vessel area (10.480.56 versus
11.050.35 mm2), IEL area (8.470.50 versus 8.760.31 mm2),
or medial area (2.010.08 versus 2.280.14 mm2). Impor-
tantly, there was no significant difference in the injury score
(2.310.11 versus 2.230.13) (Figure 2F) and stent circumfer-
ence (9.530.16 versus 9.550.28 mm2) between the 2 groups,
indicating and that experimental and control animals had a
similar degree of injury and complete stent deployment.
Effect of Bindarit on In Vivo Proliferation
Treatment with bindarit significantly reduced (by 45%,
P0.05) the number of PCNA-positive cells in the artery 7
days after stent implantation compared with control group
(Figure 3A and 3B). Results were also confirmed by Western
blot analysis (Supplemental Figure I, available online at
http://atvb.ahajournals.org).
Effect of Bindarit on
Monocyte/Macrophage Infiltration
Western blot analysis was performed to examine the effect of
bindarit on the monocyte/macrophage infiltration. The mono-
cyte/macrophage marker CD68 was highly expressed in
coronary arteries 28 days after stent implantation. Bindarit
significantly reduced (by 55%, P0.01) CD68 levels as
shown by relative densitometric analysis (Figure 3C and 3D).
Effect of Bindarit on MCP-1 Plasma Levels
A significant increase (P0.01) in MCP-1 plasma concen-
tration was observed in pigs subjected to stenting compared
with the naïve animals (1903.05172.64 pg/mL, n9, versus
885.4126.74 pg/mL, n5). Bindarit caused a significant
(P0.05) inhibition of MCP-1 plasma levels at day 28 by
30% (1369.4576.13 pg/mL, n7) (Figure 4).
Figure 3. A, Representative photomicrographs of proliferating
cell nuclear antigen (PCNA)–stained coronary arteries at day 7
after stent implantation (magnification 200). Scale bar100 m.
B, Graph showing the effect of bindarit on cell proliferation in
vivo. Results are expressed as percentage of total arterial
(medial plus neointimal) cells positive for PCNA, as described in
Methods. Data per single animal and means (bars) are presented.
C, Representative blot showing the effect of bindarit on CD68
expression in the protein extract of single coronary arteries 28
days after stenting. D, Densitometric analysis of CD68 expres-
sion levels normalized to protein levels of -actin. Data per
single animal and means (bars) are presented. *P0.05 and
**P0.01 vs control group.
Figure 4. Effect of bindarit on monocyte chemotactic protein-1
(MCP-1) plasma levels in pigs 28 days after stent implantation.
°°P0.01 vs naïve animals, *P0.05 vs control group.
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Effect of Bindarit on Porcine SMC Proliferation
Initiation and maintenance of SMC proliferation is a critical
event in the pathogenesis of intimal hyperplasia. As shown in
Figure 5, bindarit at 100 and 300 mol/L significantly
inhibited TNF--induced porcine SMC proliferation by 33%
and 50% (P0.01, n3), respectively. Cell viability (95%)
was not affected by bindarit at the concentrations used in this
study (data not shown).
Effect of Bindarit on MCP-1 Production
To determine whether the in vitro antiproliferative effect of
bindarit was associated with MCP-1 inhibition, MCP-1 pro-
tein concentration was determined by ELISA in the superna-
tants of cultured primary porcine SMCs. As shown in the
Table, stimulation of SMCs with TNF- (50 ng/mL) caused
an increase in release of MCP-1 compared with unstimulated
cells. When porcine SMCs were stimulated with TNF- in
the presence of bindarit (10–300 mol/L), a significant
inhibition of MCP-1 production was observed at 100 and
300 mol/L.
Discussion
We previously demonstrated that bindarit inhibits neointimal
formation in rodent models of vascular injury by a direct
effect on SMC proliferation and migration and by reducing
neointimal macrophage content; effects associated with the
inhibition of MCP-1 production.17 However, although small
animal models of neointimal formation have several advan-
tageous characteristics (eg, low cost, ready availability, small
size that limits the quantities of investigational drugs required
for in vivo use), on many occasions they lack efficacy in
predicting the success of interventions to inhibit restenosis in
humans.18–20 Therefore, the aim of the present study was to
evaluate the efficacy of bindarit in the preclinical model of in
stent stenosis in pigs.
In this study, we have shown that bindarit given orally
significantly reduces in-stent stenosis in the porcine coronary
stent model. When compared with the controls, stented
arteries from bindarit-treated animals showed a significant
reduction of morphometric percentage stenosis area, from
75% to 47.5%, a decrease of 37%. Seventy-five percent of the
stenosis area in the control group was a higher value than
other reports in the literature.26,27 However, as shown by our
injury score, no or minimal damage was induced to the
media. According to the Gunn23 scoring system, an average
value of2.2 indicates an IEL deformed45° in most of the
samples analyzed in the absence of medial injury. Injury
scores, external elastic lamina area, IEL area, and stent
circumference were similar in both groups, confirming the
homogeneity of the analyzed data in our model. In stented
coronary arteries from animals treated with bindarit, neointi-
mal area was significantly inhibited by 40% compared with
control animals. Importantly, bindarit shows effects similar to
those of paclitaxel- and sirolimous-coated stents on neointima
formation in porcine models.22,27 A moderate inflammation
was also observed in peri-stent areas, as assessed by the
inflammatory score, and this was reduced by 40% in
stented arteries from bindarit-treated animals.
Neointimal hyperplasia contributes to the development of
in-stent restenosis,28 and a pivotal mechanism is the loss of
differentiation of SMCs that become able to proliferate and
migrate.29 It is well known that MCP-1 not only is a potent
chemoattractant chemokine for monocytes/macrophages but
may also directly induce SMC proliferation and migration
through cell cycle proteins and intracellular proliferative
signals.2,3 Interestingly, bindarit diminished the number of
Figure 5. Effect of bindarit (10–300 mol/L) on tumor necrosis
factor- (TNF-)–induced porcine smooth muscle cell prolifera-
tion. Results are expressed as meanSEM of 3 separate experi-
ments run in triplicate. °°P0.01 vs unstimulated cells, **P0.01
vs TNF-.
Table. Effect of Bindarit on MCP-1 Production by TNF--Stimulated Porcine SMCs
MCP-1 (pg/mL)
12 h 24 h 48 h 72 h
Unstimulated cells 24232 104477 1906150 2520164
50 ng/mL TNF- 1840192* 3817215* 5120220* 5354161*
50 ng/mL TNF-10 mol/L bindarit 1637123 3450199 5450310 6030358
50 ng/mL TNF-30 mol/L bindarit 170151 3920257 4770353 5389266
50 ng/mL TNF-100 mol/L bindarit 124155† 3046152‡ 4080144‡ 3782116†
50 ng/mL TNF-300 mol/L bindarit 108836† 2430133† 3400174† 2824110†
Results are expressed as meanSEM of three experiments run in triplicate. MCP indicates monocyte chemotactic
protein; TNF, tumor necrosis factor; SMC, smooth muscle cell.
*P0.01 vs unstimulated cells.
†P0.01 vs TNF-.
‡P0.05 vs TNF-.
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arterial PCNA-positive proliferating cells 7 days after stent
implantation and monocyte/macrophage content in injured
vessels at 28 days, clearly showing either antiproliferative
and antiinflammatory activity. These effects were associated
with a significant inhibition of MCP-1 plasma levels. In-
creased levels of circulating MCP-1 in animals subjected to
vascular injury are in keeping with an active role for this
chemokine in tissue pathogenesis and correlate with epide-
miological evidence showing higher MCP-1 plasma levels
associated with human restenosis.30
Bindarit also displayed antiproliferative effects in vitro,
with significant inhibition of TNF--induced porcine SMC
proliferation. Furthermore, this was associated with a signif-
icant and concentration-related inhibition of MCP-1 amounts
measured in the supernatants. These data are in agreement
with our previous results on primary rat and mouse aortic
SMCs.17
The present study has some limitations. Although the
porcine coronary model seems to represent the human coro-
nary artery response to stenting, mimicking several clinical
conditions, including thrombosis and neointimal formation,20
it does not precisely simulate human in-stent restenosis.18,20
An important point in the present model is that stent implan-
tation was performed in normal porcine coronary arteries,
whereas in humans, much of the stent would be in contact
with atheromatous plaque and not with media. Furthermore,
in the present study the extent of in stent stenosis was
examined only at 28 days after stent implantation; for
example, longer follow-up should be performed to assess the
effect of bindarit on arterial healing.
In conclusion, here we report the use of oral administration
of bindarit as a viable approach to reduce in stent stenosis in
pigs. Importantly, preclinical studies demonstrated that bin-
darit has a safe toxicological profile (rodent LD50 2000
mg/kg PO and 600 mg/kg IP) and is devoid of immuno-
suppressive, mutagenic, and carcinogenic effects (Product
Data Sheet, Angelini Research Center). Phase I clinical
studies demonstrated that bindarit (up to a dose of 1200 mg
BID) is well tolerated and confirmed the lack of overt toxicity
suggested by preclinical studies (Product Data Sheet, Ange-
lini Research Center). Results of Phase II clinical studies
confirmed the good tolerability profile of bindarit and dem-
onstrated, at 600 mg BID, significant effects in kidney
disease patients.31,32 Currently, a double-blind, randomized,
placebo-controlled clinical trial is ongoing (“The Effects of
Bindarit in Preventing Stent Restenosis,” registered on Clini-
calTrials.gov, identifier NCT01269242), with the aim of
investigating the effect of bindarit in human coronary reste-
nosis. Evidence of bindarit efficacy could provide clinicians
with useful complementary or alternative therapeutic tools.
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Supplemental Material 
 
Figure I (A) Representative blot showing the effect of bindarit on PCNA expression in the 
protein extract of single coronary arteries 7 days after stenting. (B) Densitometric analysis of 
PCNA expression levels normalized to protein levels of β-actin. Data per single animal and 
means (bars) are presented. *P<0.05 vs control group. 
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